Dec 14, 2023
Beena Wood, Senior VP of Safety and Medical at ArisGlobal, highlights how artificial intelligence is revolutionizing patient-centricity in drug development, pointing out the factors drawing more interest in this challenge. The LifeSphere drug development platform aims to drive patient-centric guidance by providing access to real-world data and enabling patient collaboration. Beena emphasizes the importance of engaging a diverse universe of patients and leveraging AI, data analytics, and machine learning to reveal hidden insights from the data to improve drug testing and safety.
Beena explains, "Before specifically diving into how AI helps, I want to step back a bit on what the forces that drive patient-centricity are. I don't think these forces are new. They had existed, but I think they have been accelerating that patient-centricity conversation, especially with patients increasingly taking charge of their health and becoming more empowered. I think that drives the life sciences companies to focus on that and strive harder to become more patient-centric."
"I think targeted therapies are accelerating the need to have that patient-centric mindset and strategy and operational model. For that strategy to be successful, it is important to leverage the right technology to be able to listen to those patients and to have that execution of that patient-centric digital strategy. That will be critical to achieving success."
#ArisGlobal #PatientCentricity #PatientCentric #LifeSciences #Automation #AI #DrugDevelopment